Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

MTNB vs PFE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

PFE Wins Head-to-Head Institutional Verdict (6–0 across 6 Pillars · 9–1 Matrix Metrics)

PFE Overall Winner 6-Pillar Tally: MTNB 0 – 6 PFE Matrix Metrics: MTNB 1 – 9 PFE

As of Nov 19, 2026, Pfizer Inc. (PFE) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MTNB carries a Unified Composite Score of 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin), whereas PFE carries 50.2/100 (HOLD) at $27.54 (9.3x Forward P/E, 29.1% operating margin).

  • Composite vs. Pillar Nuance: While MTNB currently prints a higher short-term Unified Composite Score (54.6/100 HOLD vs. PFE 50.2/100 HOLD), PFE captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (29.1% vs. 0.0% operating margin) and revenue trajectory (-0.4% vs. -100.0% YoY).

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MTNB vs PFE
MTNB NYSE American
Matinas BioPharma Holdings, Inc.
Pharmaceutical Preparations
$0.81
-10.98% 1D
Market Cap $979,904
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -7.20β · 147% Vol
Unified Composite Score
54.6 / 100 HOLD
Tech 53.0 Fund 58.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 33
RSI-14: 33.0 · SMA20: $1.26 · SMA50: $1.47
PFE NYSE Head-to-Head Winner
Pfizer Inc.
Pharmaceutical Preparations
$27.54
-1.85% 1D
Market Cap $159.9B
TTM Revenue $63.6B
Forward P/E 9.3x
Beta / 30D Vol 0.19β · 24% Vol
Unified Composite Score
50.2 / 100 HOLD
Tech 32.0 Fund 52.0 Flow 69.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 34
RSI-14: 33.6 · SMA20: $29.45 · SMA50: $28.83

6-Pillar Scorecard Institutional Category Breakdown (MTNB 0 – 6 PFE)

Columns: Metric · MTNB · PFE
1. Valuation Multiples PFE
Forward P/E N/M 9.3x
Trailing P/E N/M 40.1x
PEG Ratio N/M 8.56x
EV / Revenue N/M 3.5x
2. Growth & Scale PFE
Revenue Growth (YoY) -100.0% -0.4%
Earnings Growth (YoY) +0.0% -9.7%
TTM Revenue (USD) N/A $63.6B
Market Cap $979,904 $159.9B
3. Profitability & Quality PFE
Gross Margin N/A 74.9%
Operating Margin 0.0% 29.1%
Net Profit Margin 0.0% 6.3%
Return on Equity (ROE) -147.5% 4.5%
4. Balance Sheet & Cash Flow PFE
Cash Generation (TTM) N/A $11.8B
Cash Flow Margin N/A 18.5%
Net Cash / Leverage $1.2M Net Cash $60.8B Net Debt (0.70x D/E)
Dividend Yield None (0.00%) 7.55%
5. Options & Positioning PFE
Options Structure Phase UNCLASSIFIED CONSOLIDATION
Current IV / %ile N/A (N/A) 23.5% (28th %ile)
Put/Call OI Skew N/A 0.59x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat PFE
OpEx & R&D Intensity N/A 45.8% of Rev ($29.1B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Scale & Operating Efficiency Moat
Supply-Chain Role Biotechnology Operator Drug Manufacturers - General Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MTNB (1) vs PFE (9)
Institutional Metric MTNB PFE Criterion Row Edge
Market Capitalization
Scale
$979,904 $159.9B Larger Scale PFE
Trailing P/E Ratio
Valuation
N/M 40.1x Lower Multiple PFE
Forward P/E Ratio
Valuation
N/M 9.3x Lower Multiple PFE
Revenue Growth (YoY)
Growth
-100.0% -0.4% Higher Growth PFE
Operating Margin (TTM)
Profitability
0.0% 29.1% Higher Margin PFE
Net Profit Margin
Profitability
0.0% 6.3% Higher Margin PFE
Return on Equity (ROE)
Capital Efficiency
-147.5% 4.5% Higher ROE PFE
52-Week Range Position
Momentum
22% ($0–$3) 50% ($24–$31) Stronger Trend PFE
Beta / 30D Volatility
Risk Regime
-7.20β · 147% Vol 0.19β · 24% Vol Lower Realized Risk PFE
Unified Institutional Score
Composite Signal
54.6 / 100 (HOLD) 50.2 / 100 (HOLD) Higher Composite MTNB
Trailing 12M Revenue (USD)
Operating Scale
N/A $63.6B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 74.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev 8.56x PEG · 3.5x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($1.2M Net Cash) $11.8B ($60.8B Net Debt (0.70x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon PFE +38.96 pp
MTNB: -46.7% · PFE: -7.74%
3M Horizon MTNB +309.38 pp
MTNB: +307.49% · PFE: -1.89%
6M Horizon MTNB +14.8 pp
MTNB: +20.93% · PFE: +6.13%
1Y Horizon PFE +39.56 pp
MTNB: -31.35% · PFE: +8.21%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period MTNB Revenue PFE Revenue MTNB Op. Margin PFE Op. Margin Margin Leader
FY2018 $0M $40.8B -12230.9% 27.3% PFE
FY2019 $0M $40.9B -21067.4% 39.2% PFE
FY2020 $0M $41.6B -15288.4% 22.0% PFE
FY2021 $0M $73.6B -74954.5% 29.8% PFE
FY2022 $0M $91.8B -771.3% 34.2% PFE
FY2023 $0M $50.9B -2168.4% 4.2% PFE
FY2024 N/A $63.6B N/A 12.6% PFE
FY2025 N/A $62.6B N/A 12.4% PFE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MTNB UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MTNB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
PFE CONSOLIDATION
55d in phase · OBV DISTRIBUTION
Current IV 23.5%
IV Percentile 28th %ile
Put/Call OI Skew 0.59x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow DISTRIBUTION
Exact PFE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LIVE OPTIONS CHAIN · T+5 TRADING DAY HORIZON Spot $28.86 · IV 25.6%

PFE Simulated 5-Day Option Payoffs vs. Owning 100 Shares ($2,886)

Compare $2,886 in 100-share capital outlay against risk-defined 5-day vertical spreads, put-wall income, and 3-leg structures at 25.6% ATM IV.

5-DAY BULLISH SWING Liq A

Dec 18 $29 / $30 Bull Call Spread

Buy 2x $29C · Sell 2x $30C · 31d

Net Entry $84 Debit
T+5d @ +5% Move +$52 (+62%)
Max Risk / Buffer $84 Capped
5d Edge & Liquidity 0.9x R:R · Liq A
Simulate 5-Day Payoff →
PUT-WALL MONTHLY INCOME Liq A

Jan 15 '27 $27 / $25 Bull Put Spread

Sell 2x $27P · Buy 2x $25P · 59d

Net Entry $58 Credit
Max Credit / Yield +$58 (+17.0% RoM)
Max Risk / Buffer -7.4% Cushion ($342 Mgn)
5d Edge & Liquidity 77% PoP · Liq A
Simulate 5-Day Payoff →
ASYMMETRIC 3-LEG STRUCTURE Liq C

Dec 24 $27P / $29-$31C Seagull

Sell 1x $27P · Buy 1x $29/$31C · 37d

Net Entry $40 Debit
T+5d @ +5% Move +$66 (+14.3% RoM)
Max Risk / Buffer -6.4% Put Cushion ($459 Mgn)
5d Edge & Liquidity 0.7x R:R · Liq C
Simulate 5-Day Payoff →

Simulated T+5 trading day payoffs use live option midpoints, bid-ask spread adjustments, and implied volatility skew for educational scenario modeling only — not personalized investment advice. Options involve substantial risk.

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MTNB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $979,904 market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
PFE Moat Profile Scale & Operating Efficiency Moat
Drug Manufacturers - General Operator
Competes within the Drug Manufacturers - General value chain with $159.9B market capitalization and 29.1% operating margin.
OpEx & R&D Reinvestment 45.8% of Rev ($29.1B)
90D Engineering Disclosures 0 Published

Investor FAQ MTNB vs PFE Key Questions & Quantitative Answers

As of Nov 19, 2026, Pfizer Inc. (PFE) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 6–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). MTNB carries a Unified Composite Score of 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin), whereas PFE carries 50.2/100 (HOLD) at $27.54 (9.3x Forward P/E, 29.1% operating margin). Composite vs. Pillar Nuance: While MTNB currently prints a higher short-term Unified Composite Score (54.6/100 HOLD vs. PFE 50.2/100 HOLD), PFE captures the overall institutional head-to-head verdict (9–1 matrix metrics and 6–0 across the 6 pillars) due to superior fundamental profitability (29.1% vs. 0.0% operating margin) and revenue trajectory (-0.4% vs. -100.0% YoY).

PFE leads the Growth & Scale pillar: MTNB posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with PFE at -0.4% YoY revenue growth and -9.7% YoY earnings growth on $63.6B TTM revenue (74.9% gross margin, 29.1% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), MTNB cumulative revenue shifted N/A while PFE shifted +53.3%. In operating R&D and SG&A reinvestment, MTNB deploys N/A (0 90-day corporate R&D disclosures) versus 45.8% of Rev ($29.1B) (0 disclosures) for PFE.

PFE screens cheaper on headline valuation multiples. MTNB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas PFE trades at 9.3x Forward P/E, 40.1x Trailing P/E, 8.56x PEG, and 3.5x EV/Revenue (18.5% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MTNB (-147.5% ROE) versus PFE (4.5% ROE) capital efficiency.

In options market volatility and institutional positioning, MTNB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.20β · 147% Vol realized risk). By comparison, PFE carries 23.5% implied volatility (28th %ile, Balanced (25th–60th %ile)), a 0.59x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.19β · 24% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.